GlassScriptPhysician profile
Sofia Reyes Weinstock
NPI 1235737461
$364.40
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $77.40 · 2022: $287.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $147.50 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $79.34 | 2022 | |
| Avanir Pharmaceuticals, INC. | $34.48 | 2021-2022 | |
| Lilly USA, LLC | $28.32 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.53 | 2022 | |
| Kyowa Kirin, INC. | $20.00 | 2021 | |
| Pfizer INC. | $17.23 | 2021 | |
| Glaxosmithkline, LLC. | $16.00 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofia Weinstock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.